Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study
Nicolas Petitdidier(Université Paris-Est Créteil), Aurélien Amiot(Université Paris-Est Créteil), Robert Benamouzig(Assistance Publique – Hôpitaux de Paris), Pauline Jouët(Hôpital Ambroise-Paré), Franck Carbonnel(Université Paris-Saclay), Laurent Beaugerie(Assistance Publique – Hôpitaux de Paris), Véred Abitbol(Hôpital Cochin), Lysiane Marthey(Université Paris-Saclay), Matthieu Allez(Inserm), Xavier Amiot(Sorbonne Université), Anne-Laure Pelletier(Lyon 1 Université), Sylvie Rajca(Université Paris Cité), Yoram Bouhnik(Clinique Ambroise Paré), Georgia Malamut(Délégation Paris 5), Anne Bourrier(Sorbonne Université), Xavier Tréton(Hôpital Beaujon)
Cited by 7
Related Papers
Potential of fecal microbiota for early‐stage detection of colorectal cancer
|Molecular Systems Biology|2014|1.4k
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
|Annals of Oncology|2017|1.3k
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
|Nature Reviews Clinical Oncology|2016|1.1k
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|1k